🔗 Share this article

Former Prime Minister Rishi Sunak has strengthened his campaign for a targeted screening programme for prostate cancer.

In a recent conversation, he expressed being "certain of the immediate need" of establishing such a programme that would be cost-effective, achievable and "protect innumerable lives".

These comments surface as the National Screening Advisory Body reconsiders its ruling from five years ago not to recommend regular testing.

Media reports indicate the committee may continue with its present viewpoint.

Athlete Adds Support to Movement

Champion athlete Chris Hoy, who has late-stage prostate gland cancer, advocates for middle-aged males to be screened.

He recommends decreasing the age threshold for requesting a PSA blood screening.

Currently, it is not routinely offered to healthy individuals who are under 50.

The PSA examination remains debated however. Levels can rise for reasons besides cancer, such as bacterial issues, resulting in misleading readings.

Opponents contend this can lead to unnecessary treatment and adverse effects.

Focused Testing Initiative

The suggested screening programme would focus on males between 45 and 69 with a genetic predisposition of prostate gland cancer and black men, who experience double the risk.

This population comprises around 1.3 million individuals in the United Kingdom.

Charity estimates suggest the initiative would require £25 million annually - or about eighteen pounds per patient - akin to intestinal and breast examination.

The estimate involves one-fifth of eligible men would be contacted each year, with a 72% uptake rate.

Medical testing (imaging and tissue samples) would need to expand by twenty-three percent, with only a moderate increase in NHS staffing, according to the analysis.

Clinical Community Reaction

Several medical experts are sceptical about the benefit of screening.

They argue there is still a risk that patients will be intervened for the disease when it is not absolutely required and will then have to endure side effects such as bladder issues and erectile dysfunction.

One leading urology expert commented that "The challenge is we can often detect disease that might not necessitate to be treated and we risk inflicting harm...and my worry at the moment is that risk to reward ratio isn't quite right."

Patient Perspectives

Patient voices are also affecting the conversation.

A particular instance concerns a man in his mid-sixties who, after asking for a PSA test, was detected with the cancer at the age of fifty-nine and was informed it had progressed to his pelvis.

He has since experienced chemical therapy, radiation treatment and hormonal therapy but is not curable.

The individual advocates screening for those who are potentially vulnerable.

"This is essential to me because of my sons – they are in their late thirties and early forties – I want them tested as quickly. If I had been screened at fifty I am confident I might not be in the position I am currently," he said.

Future Steps

The National Screening Committee will have to weigh up the evidence and viewpoints.

While the latest analysis suggests the consequences for personnel and availability of a examination system would be manageable, others have contended that it would redirect scanning capacity from patients being managed for alternative medical problems.

The continuing debate highlights the multifaceted equilibrium between prompt identification and possible excessive intervention in prostate gland cancer treatment.